STADA boasts of impressive feats as growth goes on

STADA Arzneimittel (SAZ: ETR) announced impressive sales growth for the first half of 2023 on Tuesday.

The Germany-based company’s sales grew by 16% to 2.1 billion euros ($2.3 billion) for the six-month period, while earnings before interest, taxes, depreciation and amortization (EBITDA) rose by 30% to 509 million euros.

STADA says that its best half-year results to date were achieved thanks to above-market performance across its three strategic business segments of Consumer Healthcare, Generics and Specialty Pharmaceuticals. All regions contributed to the sales and profit development.